John McCamant Scans Under the Radar for Promising Biotechs InvestorIdeas.com (press release) Vice president of sales Michael Crum arrived in January after 13 years at Genentech ( Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments including Rituxan (rituximab), Avastin (bevacizumab) and Herceptin (trastuzumab). A total ... |
